排序方式: 共有6条查询结果,搜索用时 78 毫秒
1
1.
2.
Grogan Dayton Bray David P. Cosgrove Megan Boucher Andrew Erwood Andrew Linder Daniel F. Mendoza Pia Morales Bryan Pradilla Gustavo Nduom Edjah K. Neill Stewart Olson Jeffrey J. Hoang Kimberly B. 《Journal of neuro-oncology》2022,157(1):187-195
Journal of Neuro-Oncology - Genetic analyses of gliomas have identified key molecular features that impact treatment paradigms beyond conventional histomorphology. Despite at-times lower grade... 相似文献
3.
Edjah K. Nduom Jun Wei Nasser K. Yaghi Neal Huang Ling-Yuan Kong Konrad Gabrusiewicz Xiaoyang Ling Shouhao Zhou Cristina Ivan Jie Qing Chen Jared K. Burks Greg N. Fuller George A. Calin Charles A. Conrad Caitlin Creasy Krit Ritthipichai Laszlo Radvanyi Amy B. Heimberger 《Neuro-oncology》2016,18(2):195-205
Background
Therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) and PD-1/PD-L1 has demonstrated tumor regression in clinical trials, and phase 2 trials are ongoing in glioblastoma (GBM). Previous reports have suggested that responses are more frequent in patients with tumors that express PD-L1; however, this has been disputed. At issue is the validation of PD-L1 biomarker assays and prognostic impact.Methods
Using immunohistochemical analysis, we measured the incidence of PD-L1 expression in 94 patients with GBM. We categorized our results according to the total number of PD-L1-expressing cells within the GBMs and then validated this finding in ex vivo GBM flow cytometry with further analysis of the T cell populations. We then evaluated the association between PD-L1 expression and median survival time using the protein expression datasets and mRNA from The Cancer Genome Atlas.Results
The median percentage of PD-L1-expressing cells in GBM by cell surface staining is 2.77% (range: 0%–86.6%; n = 92), which is similar to the percentage found by ex vivo flow cytometry. The majority of GBM patients (61%) had tumors with at least 1% or more PD-L1-positive cells, and 38% had at least 5% or greater PD-L1 expression. PD-L1 is commonly expressed on the GBM-infiltrating T cells. Expression of both PD-L1 and PD-1 are negative prognosticators for GBM outcome.Conclusions
The incidence of PD-L1 expression in GBM patients is frequent but is confined to a minority subpopulation, similar to other malignancies that have been profiled for PD-L1 expression. Higher expression of PD-L1 is correlated with worse outcome. 相似文献4.
Nduom EK Bouras A Kaluzova M Hadjipanayis CG 《Neurosurgery Clinics of North America》2012,23(3):439-449
Glioblastoma remains one of the most difficult cancers to treat and represents the most common primary malignancy of the brain. Although conventional treatments have found modest success in reducing the initial tumor burden, infiltrating cancer cells beyond the main mass are responsible for tumor recurrence and ultimate patient demise. Targeting residual infiltrating cancer cells requires the development of new treatment strategies. The emerging field of cancer nanotechnology holds promise in the use of multifunctional nanoparticles for imaging and targeted therapy of glioblastoma. This article examines the current state of nanotechnology in the treatment of glioblastoma and directions of further study. 相似文献
5.
Lynes John Acquaye Alvina A. Sur Hannah Nwankwo Anthony Sanchez Victoria Vera Elizabeth Wu Tianxia Theeler Brett Armstrong Terri S. Gilbert Mark R. Nduom Edjah K. 《Journal of neuro-oncology》2020,149(1):161-170
Journal of Neuro-Oncology - Diffuse midline gliomas are rare midline CNS malignancies that primarily affect children but can also affect adults. While radiation is standard treatment, prognosis... 相似文献
6.
The kuru infectious agent is a unique geographic isolate distinct from Creutzfeldt–Jakob disease and scrapie agents 下载免费PDF全文
Laura Manuelidis Trisha Chakrabarty Kohtaro Miyazawa Nana-Aba Nduom Kaitlin Emmerling 《Proceedings of the National Academy of Sciences of the United States of America》2009,106(32):13529-13534
Human sporadic Creutzfeldt–Jakob disease (sCJD), endemic sheep scrapie, and epidemic bovine spongiform encephalopathy (BSE) are caused by a related group of infectious agents. The new U.K. BSE agent spread to many species, including humans, and clarifying the origin, specificity, virulence, and diversity of these agents is critical, particularly because infected humans do not develop disease for many years. As with viruses, transmissible spongiform encephalopathy (TSE) agents can adapt to new species and become more virulent yet maintain fundamentally unique and stable identities. To make agent differences manifest, one must keep the host genotype constant. Many TSE agents have revealed their independent identities in normal mice. We transmitted primate kuru, a TSE once epidemic in New Guinea, to mice expressing normal and ≈8-fold higher levels of murine prion protein (PrP). High levels of murine PrP did not prevent infection but instead shortened incubation time, as would be expected for a viral receptor. Sporadic CJD and BSE agents and representative scrapie agents were clearly different from kuru in incubation time, brain neuropathology, and lymphoreticular involvement. Many TSE agents can infect monotypic cultured GT1 cells, and unlike sporadic CJD isolates, kuru rapidly and stably infected these cells. The geographic independence of the kuru agent provides additional reasons to explore causal environmental pathogens in these infectious neurodegenerative diseases. 相似文献
1